Evaluation of vancomycin use in a large university-affiliated hospital in eastern France in 1999

被引:14
作者
Floret, N
Thouverez, M
Thalamy, B
Estavoyer, JM
Talon, D [1 ]
机构
[1] CHU Besancon, Serv Hyg Hosp, F-25030 Besancon, France
[2] CHU Besancon, Serv Malad Infect & Trop, F-25030 Besancon, France
来源
PHARMACY WORLD & SCIENCE | 2001年 / 23卷 / 03期
关键词
appropriate use; empirical therapy; glycopeptide resistance; hospital pharmacy; specific therapy; vancomycin;
D O I
10.1023/A:1011269131048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: In 1999, we conducted a retrospective drug utilization review to determine the volume and pattern of vancomycin use in a university-affiliated hospital in eastern France. Methods: Total vancomycin use was determined and expressed as vancomycin courses per 100 admitted patients and defined daily doses (DDD) of vancomycin per 100 patient-days. The indication for vancomycin use was classified as appropriate or inappropriate according to the guidelines issues by the HICPAC. Results: A total of 311 vancomycin courses were given, as 2098 DDD, giving crude incidences of 1.17 courses per 100 admitted patients and of 1.19 defined daily doses per 100 patient-days. The frequency of appropriate courses was 66.7%. Of the 63 inappropriate courses of vancomycin, 39.7% and 28.6% were empiric therapy for nosocomial and community-acquired infections, respectively, 20.6% and 6.3% were specific therapy for nosocomial and community-acquired infections, respectively, and 4.7% were prophylactic. Conclusions: This study shows that vancomycin use in our hospital resulted in a lower selection pressure than has been reported for US university-affiliated hospitals and that comprehensive programs to improve use of vancomycin are needed in our institution.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 32 条
[1]  
AMSDEN GW, 1995, PRINCIPLES PRACTICE, P492
[2]  
ANGIM AM, 1997, ARCH INTERN MED, V157, P1132
[3]  
[Anonymous], 1995, INFECT CONT HOSP EP, V16, P105
[4]   Clinical and molecular epidemiology of hospital Enterococcus faecium isolates in eastern France [J].
Bertrand, X ;
Thouverez, M ;
Bailly, P ;
Cornette, C ;
Talon, D .
JOURNAL OF HOSPITAL INFECTION, 2000, 45 (02) :125-134
[5]  
BOYCE JM, 1995, INFECT CONT HOSP EP, V16, P634
[6]   COMPARATIVE EFFICACY OF DAPTOMYCIN, VANCOMYCIN, AND CLOXACILLIN FOR THE TREATMENT OF STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN RATS AND ROLE OF TEST CONDITIONS IN THIS DETERMINATION [J].
CANTONI, L ;
GLAUSER, MP ;
BILLE, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (12) :2348-2353
[7]  
Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P597
[8]   THE EPIDEMIOLOGY OF INTRAVENOUS VANCOMYCIN USAGE IN A UNIVERSITY HOSPITAL - A 10-YEAR STUDY [J].
ENA, J ;
DICK, RW ;
JONES, RN ;
WENZEL, RP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (05) :598-602
[9]   Vancomycin use in a university medical center: Effect of a vancomycin continuation form [J].
Evans, ME ;
Millheim, ET ;
Rapp, RP .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (06) :417-420
[10]   Enterococci and vancomycin resistance [J].
French, GL .
CLINICAL INFECTIOUS DISEASES, 1998, 27 :S75-S83